Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Could This Be Novartis' Next Blockbuster Medicine?
08:45am, Friday, 27'th Jan 2023
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug.
Is a Beat on the Cards for Novo Nordisk (NVO) in Q4 Earnings?
03:20pm, Thursday, 26'th Jan 2023 Zacks Investment Research
Novo Nordisk's (NVO) top line is likely to have been driven by sales of its Diabetes and Obesity Care products in the fourth quarter of 2022.
Novartis' (NVS) Unit to Acquire Astellas' Rights of Mycamine
05:27pm, Tuesday, 24'th Jan 2023 Zacks Investment Research
Novartis' (NVS) generic unit Sandoz is set to acquire rights to the antifungal product Mycamine from Astellas.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
01:50pm, Monday, 23'rd Jan 2023 Zacks Investment Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
3 Drug Stocks With Promising Pipelines for 2023
10:03am, Monday, 23'rd Jan 2023
The world of pharmaceutical progress happens incrementally and exponentially. That is, therapies are iteratively improved while breakthrough treatments are also created and discovered.
Novartis CEO: Nations pulling back on health care spending ‘has long-term consequences'
02:40pm, Friday, 20'th Jan 2023
Novartis CEO Vasant Narasimhan joins Yahoo Finance Live's Julie Hyman at the 2023 World Economic Forum in Davos, Switzerland, to discuss drug pricing, the future of medicine, the impact that health ca
Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide
05:19pm, Thursday, 19'th Jan 2023 Benzinga
Cantor Fitzgerald published around 40-page deep dive ahead of Novo Nordisk A/S's (NYSE: NVO) SELECT CV outcomes study, which is guided to complete in ~mid-2023.
In large-cap land, there two two o
The Zacks Analyst Blog Highlights Nike, Novartis, Wells Fargo, Broadcom and Anheuser-Busch
02:25pm, Wednesday, 18'th Jan 2023 Zacks Investment Research
Nike, Novartis, Wells Fargo, Broadcom and Anheuser-Busch are part of the Zacks top Analyst Blog.
Top Stock Reports for NIKE, Novartis & Wells Fargo
06:07pm, Tuesday, 17'th Jan 2023 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including NIKE, Inc. (NKE), Novartis AG (NVS) and Wells Fargo & Company (WFC).
Incyte (INCY) Up 7% in a Year: Will the Momentum Continue?
02:36pm, Tuesday, 17'th Jan 2023 Zacks Investment Research
Incyte (INCY) outperforms the biotech industry in the past year and the momentum is anticipated to continue in 2023 as well.
I'll Avoid These Sectors In 2023
08:39am, Sunday, 15'th Jan 2023 Seeking Alpha
I wrote an article about which sectors I intend to focus on for this year, with a number of examples. Find out which sectors I'll avoid in 2023.
I'll Avoid These Sectors In 2023
03:39am, Sunday, 15'th Jan 2023
I wrote an article about which sectors I intend to focus on for this year, with a number of example picks for each sector. In this article, it's the opposite. I will show you what sectors I will try t
Deciphera (DCPH) Rises 70% in the Past 6 Months: Here's Why
03:15pm, Friday, 13'th Jan 2023 Zacks Investment Research
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.
Novartis generated $40 billion in innovative medicine sales, says CEO
12:51pm, Tuesday, 10'th Jan 2023
CNBC's Meg Tirrell sits down with Dr. Vas Narasimhan, CEO of Novartis International on drug development and future of the company.
Ranking The Top 10 Pharmaceuticals By Pipeline
11:44pm, Monday, 09'th Jan 2023
The pipeline is the heart of a drug discovery company. As such, analyzing the health of a pipeline can lead to suggestions about future performance.
